Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin for Prevention of New Onset Diabetes After Renal Transplantation
NCT02849899Phase 3Completed
- Sponsor
- CHU de Besançon
- Start
- Oct 2018
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vildagliptin in diabetes mellitus (DM), sponsored by CHU de Besançon. Started Oct 2018; status: completed.
02
Drugs
vildagliptin
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT02849899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02849899.